AEON Biopharma (AEON) Research & Development (2022 - 2026)

AEON Biopharma has disclosed Research & Development across 5 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Research & Development rose 176.13% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $6.2 million (up 5.26% YoY), while the FY2025 annual figure was $4.1 million, down 71.13% from the prior year.
• Research & Development came in at $2.9 million for Q2 2026 at AEON Biopharma, up from $1.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.5 million in Q4 2022 to a low of $597000.0 in Q3 2025.
• Average Research & Development over 5 years is $4.5 million, with a median of $3.7 million recorded in 2024.
• Year-over-year, Research & Development slumped 85.61% in 2025 and surged 176.13% in 2026.
• Over 5 years, Research & Development stood at $9.5 million in 2022, then tumbled by 32.96% to $6.4 million in 2023, then slumped by 52.46% to $3.0 million in 2024, then tumbled by 47.02% to $1.6 million in 2025, then surged by 82.6% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $2.9 million in Q2 2026, $1.6 million in Q4 2025, and $597000.0 in Q3 2025.